San Diego—TargeGen Inc. has initiated a single-site phase I clinical trial involving TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of age-related macular degeneration (AMD) and other debilitating diseases of the eye.
The year 2006 may be characterized as an interesting one in cataract surgery, according to ophthalmologists who are opinion leaders in the field.
Many factors play a role in wound healing after epi-LASIK. For example, use of nonsteroidal anti-inflammatory drugs (NSAIDs) after surgery, advanced age, and a compromised tear film have been associated with delayed wound healing, whereas younger age, healthy tear film, and certain nutritional supplements have been associated with rapid wound healing.
Hinsdale, IL—Preoperative topical application of semi-frozen balanced salt solution (BSS) given immediately before the epi-keratome pass is a highly effective technique for significantly reducing or even eliminating pain after epi-LASIK, said Bruce Larson, MD, who is a clinical instructor, Loyola University Medical Center, Maywood, IL, and in private practice in Hinsdale, IL.
Triamcinolone acetonide injections for macular edema associated with retinal vein occlusion have become a therapeutic mainstay, but conflicting data have emerged about the safety of these injections, and some reports indicate that visual stabilization rather than visual improvement is occurring.
Results of a recent small study suggest that periorbital infections secondary to methicillin-resistant Staphylococcus aureus (MRSA) may be on the rise.
Oral antiviral medications offer an effective, more convenient option compared with topical antiviral therapy for patients with acute infectious ulcers associated with herpes simplex keratitis, increasing the likelihood of therapy adherence, Deborah P. Langston, MD, FACS, told a full-capacity crowd at a symposium on eye infections Monday
Neuroprotection, a strategy to slow or prevent the death of retinal ganglion cells, offers the possibility of slowing the rate of glaucomatous progression and preventing blindness. But although the underlying theory appears to be sound, much has yet to be learned through basic and clinical research before neuroprotection could become an integral part of glaucoma therapy.